Home・Lista de Ações・United Therapeutics Corp

United Therapeutics Corp

Fechado

SetorSaúde

536.85 1.36

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

511.5

Máximo

532.71

Indicadores-chave
By Trading Economics
Rendimento	-89M 275M
Vendas	-8.7M 782M
P/E Médio do Setor	19.108 68.51
EPS	5.82
Margem de lucro	35.176
Funcionários	1,400
EBITDA	-180M 344M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+26.23% upside

Dividendos
By Acuity
Próximos Ganhos	28 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1B 26B
Abertura anterior	535.49
Fecho anterior	536.85

Sentimento de Notícias

By Acuity

91%

12 / 340 Ranking em Healthcare

United Therapeutics Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de ago. de 2026, 23:01 UTC

United Therapeutics Corp. shares are higher in after-market trading, continuing a steady increase since Thursday's close and remaining above the 20-day moving average.

5 de ago. de 2026, 20:02 UTC

News

Social Media

United Therapeutics reported second-quarter revenues of $783.3 million, missing estimates of $805.6 million, while EPS of $7.27 exceeded expectations by $0.18.

4 de ago. de 2026, 23:51 UTC

Shares of United Therapeutics Corp. are lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month trading range.

3 de ago. de 2026, 19:16 UTC

Shares of United Therapeutics Corp are lower today, trading near the lower end of their one-month range amid a broader market rally in other sectors.

30 de jul. de 2026, 14:36 UTC

Event

United Therapeutics shares are higher following the publication of full ADVANCE OUTCOMES study results in The Lancet, pending FDA approval for ralinepag.

29 de jul. de 2026, 20:51 UTC

Event

United Therapeutics shares are higher in after-market trading following The Lancet's publication of results from the ADVANCE OUTCOMES study on Ralinepag for PAH.

28 de jul. de 2026, 18:21 UTC

United Therapeutics Corp. shares are lower today, continuing a decline since Monday's close amid broader market trends and three consecutive sessions of lower finishes.

24 de jul. de 2026, 16:36 UTC

News

Social Media

United Therapeutics appointed Victor Dzau to its Board of Directors, enhancing its strategic direction. Shares are modestly higher since Thursday's close.

22 de jul. de 2026, 19:41 UTC

News

United Therapeutics filed an $833.4 million shelf registration for 1.5 million shares, contributing to downward pressure on shares amid broader market movements.

21 de jul. de 2026, 16:56 UTC

United Therapeutics Corp is seeing modest gains today, with positive sentiment from Asian markets contributing to overall investor optimism. No specific news was identified.

Comparação entre Pares

Variação de preço

United Therapeutics Corp Previsão

Preço-alvo

By TipRanks

26.23% parte superior

Previsão para 12 meses

Média 655.13 USD 26.23%

Máximo 714 USD

Mínimo 515 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para United Therapeutics Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para United Therapeutics Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

12 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.